Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

Acute myeloid leukemia (AML) patients with FLT3/ITD mutations have a poor prognosis. Monotherapy with selective FLT3 tyrosine kinase inhibitors (TKIs) have shown transient and limited efficacy due to the development of resistance. Arsenic trioxide (ATO, As(2)O(3)) has been proven effective in treati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Nagai, Kozo, Hou, Lihong, Li, Li, Nguyen, Bao, Seale, Tessa, Shirley, Courtney, Ma, Hayley, Levis, Mark, Ghiaur, Gabriel, Duffield, Amy, Small, Donald
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2018
Schlagworte:
Priority Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152471/
https://ncbi.nlm.nih.gov/pubmed/30250637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25972
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge